Interventional Oncology Devices – Market Insights – Japan

The Japanese Interventional oncology market will see marginal growth through 2035, due to limited adoption of minimally invasive interventional oncology procedures, substantiated by Japanese guidelines, stringent device approval process, biennial reimbursement cuts, declining overall population, and increasing developments in systemic anticancer drugs.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional oncology devices in Japan from 2019 to 2035.

Clinical guidelines influence the adoption of interventional oncology devices in Japan.

Which devices are favored by the clinical guidelines?

What are the recent revisions in the clinical guidelines, and how will they impact the adoption of various devices in the Japanese market?

How will the revised clinical guidelines impact market competitors?

Reimbursement will be an important factor in the adoption of interventional oncology procedures in Japan.

What is the reimbursement scenario in the country, and how will it impact the adoption of interventional oncology devices in this market?

Which devices are most impacted by the biennial reimbursement cuts in this market?

Positive clinical data will play an important role in driving the adoption of interventional oncology devices.

Which clinical trials were recently conducted in this market?

What is the expected impact of these clinical trials on market dynamics and device adoption?

Stringent regulatory framework and device approval delays will impact the interventional oncology device market in Japan.

How have regulatory approval delays impacted the Japanese interventional oncology device market?

Which devices are anticipated to enter the Japanese market within the forecast period?

Market dynamics will change over the forecast period with anticipated entry of novel devices in this market.

What are the recent developments in the IRE device and radioembolization sphere spaces, and how have those developments impacted the estimated launches of these products?